PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsCabozantinib
Cometriq(cabozantinib)
Cabometyx, Cometriq (cabozantinib) is a small molecule pharmaceutical. Cabozantinib was first approved as Cometriq on 2012-11-29. It is used to treat renal cell carcinoma in the USA. It has been approved in Europe to treat hepatocellular carcinoma, renal cell carcinoma, and thyroid neoplasms. The pharmaceutical is active against hepatocyte growth factor receptor and vascular endothelial growth factor receptor 2. In addition, it is known to target proto-oncogene tyrosine-protein kinase receptor Ret.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
urogenital diseasesD000091642
endocrine system diseasesD004700
Trade Name
FDA
EMA
Cabometyx, Cometriq
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cabozantinib s-malate
Tradename
Company
Number
Date
Products
COMETRIQExelixisN-203756 RX2012-11-29
2 products, RLD, RS
CABOMETYXExelixisN-208692 RX2016-04-25
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
cabometyxNew Drug Application2025-02-04
cometriqNew Drug Application2025-02-04
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
renal cell carcinomaEFO_0000376D002292—
Agency Specific
FDA
EMA
Expiration
Code
CABOZANTINIB S-MALATE, CABOMETYX, EXELIXIS INC
2028-09-17ODE-375
2026-01-14ODE-227
2024-09-17I-873
2024-01-22I-854
Patent Expiration
Patent
Expires
Flag
FDA Information
Cabozantinib S-Malate, Cabometyx, Exelixis Inc
97243422033-07-09DP
112983492032-02-10DP
100348732031-07-18U-2488
100397572031-07-18U-1480
88777762030-10-08DS, DPU-1617, U-3225
110914392030-01-15DP
110914402030-01-15DP
110980152030-01-15U-1220, U-1480, U-1617, U-2488, U-3225
75794732026-08-14DS, DP
84972842024-09-24U-1220, U-1480, U-2488
Cabozantinib S-Malate, Cometriq, Exelixis
97177202032-02-10DP
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01E: Protein kinase inhibitors, antineoplastic and immunomodulating agents
— L01EX: Other protein kinase inhibitors in atc
— L01EX07: Cabozantinib
HCPCS
No data
Clinical
Clinical Trials
273 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Thyroid neoplasmsD013964EFO_0003841——11——2
Thyroid diseasesD013959—E00-E07—11——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CarcinomaD002277—C80.0—4——1317
Renal cell carcinomaD002292EFO_0000376——2——1315
NeoplasmsD009369—C80—5———5
Neuroendocrine tumorsD018358EFO_1001901D3A.8—2———2
Hepatocellular carcinomaD006528—C22.0—2———2
Liver neoplasmsD008113EFO_1001513C22.0—2———2
OsteosarcomaD012516———2———2
PheochromocytomaD010673———1———1
AdenocarcinomaD000230———1———1
Anaplastic thyroid carcinomaD065646———1———1
Show 14 more
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCabozantinib
INNcabozantinib
Description
Cabozantinib is a dicarboxylic acid diamide that is N-phenyl-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in which the hydrogen at position 4 on the phenyl ring is substituted by a (6,7-dimethoxyquinolin-4-yl)oxy group. A multi-tyrosine kinase inhibitor, used (as its malate salt) for the treatment of progressive, metastatic, medullary thyroid cancer. It has a role as a tyrosine kinase inhibitor and an antineoplastic agent. It is a member of quinolines, an organofluorine compound, an aromatic ether and a dicarboxylic acid diamide.
Classification
Small molecule
Drug classtyrosine kinase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC
Identifiers
PDB—
CAS-ID849217-68-1
RxCUI—
ChEMBL IDCHEMBL2105717
ChEBI ID72317
PubChem CID25102847
DrugBankDB08875
UNII ID1C39JW444G (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
RET
RET
Organism
Homo sapiens
Gene name
RET
Gene synonyms
CDHF12, CDHR16, PTC, RET51
NCBI Gene ID
5979
Protein name
proto-oncogene tyrosine-protein kinase receptor Ret
Protein synonyms
Cadherin family member 12, cadherin-related family member 16, Proto-oncogene c-Ret, rearranged during transfection, ret proto-oncogene (multiple endocrine neoplasia and medullary thyroid carcinoma 1, Hirschsprung disease), RET receptor tyrosine kinase
Uniprot ID
Q9BTB0
Mouse ortholog
Ret (19713)
proto-oncogene tyrosine-protein kinase receptor Ret (P35546)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Cometriq – Exelixis
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Cabometyx – Exelixis
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 11,661 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
37,852 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use